Effect of Local Injection of Umbilical Cord Blood Derived Serum versus Local Injection of Platelet Rich Plasma in the Treatment of Striae Distensae

Evaluation of Effect of Local Injection of Umbilical Cord Blood Derived Serum versus Local Injection of Platelet Rich Plasma in the Treatment of Striae Distensae(A randomized controlled intervention study)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221130056672N2

Enrollment

Registered

2023-11-25

Start date

2023-12-22

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Striae Distensae.

Interventions

Intervention 1: Intervention group: Treated Local Injection of Umbilical Cord Blood Derived Serum. Intervention 2: Control group: Treated Local Injection of Platelet Rich Plasma.

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 50 years Full satisfaction of the participant in the plan Has striae alba (with all three degrees of mild, moderate, severe)

Exclusion criteria

Exclusion criteria: Inflammatory acne Active herpes labialis Local infections in the treatment area Prone to keloid Malignancy Pregnancy Breastfeeding Use of drugs that can affect bleeding or clotting mechanism Immunosuppression Use of local and systemic steroids Disease systemic diseases (such as high blood pressure ,Diabetes ,heart, kidney and liver diseases) The use of exfoliators 4 weeks before treatment In places where botulinum injection has been done, should not be done due to the possibility of microneedle toxin release.

Design outcomes

Primary

Measure	Time frame
Epidermis and dermis thickness. Timepoint: Before the start of the intervention and two months after the end of the treatment period (Four months after the start of the treatment). Method of measurement: Skin Scanner.;The amount of collagen formation. Timepoint: Before the start of the intervention and two months after the end of the treatment period (Four months after the start of the treatment). Method of measurement: Visoface.	—

Measure

Time frame

Epidermis and dermis thickness. Timepoint: Before the start of the intervention and two months after the end of the treatment period (Four months after the start of the treatment). Method of measurement: Skin Scanner.;The amount of collagen formation. Timepoint: Before the start of the intervention and two months after the end of the treatment period (Four months after the start of the treatment). Method of measurement: Visoface.

—

Secondary

Measure	Time frame
Safety. Timepoint: At the beginning of the intervention, at each re-visit session and two months after the end of the treatment period (four months after the start of the treatment). Method of measurement: Patient history.;Effectiveness. Timepoint: At the beginning of the intervention, at each re-visit session and two months after the end of the treatment period (four months after the start of the treatment). Method of measurement: Patient satisfaction.	—

Measure

Time frame

Safety. Timepoint: At the beginning of the intervention, at each re-visit session and two months after the end of the treatment period (four months after the start of the treatment). Method of measurement: Patient history.;Effectiveness. Timepoint: At the beginning of the intervention, at each re-visit session and two months after the end of the treatment period (four months after the start of the treatment). Method of measurement: Patient satisfaction.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEhsan Taghiabadi

Tehran University of Medical Sciences

etaghiabadi@sina.tums.ac.ir+98 21 2665 7438

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026